Navigation Links
Cardiome Pharma Corp. Announces Final Results of Tender Offer
Date:10/16/2009

    NASDAQ: CRME    TSX: COM

VANCOUVER, Oct. 16 /PRNewswire-FirstCall/ - Cardiome Pharma Corp. (NASDAQ: CRME / TSX: COM) ("Cardiome" or the "Company") announced the final results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009. Cardiome has accepted 6,470,588 of its common shares for purchase and cancellation at a purchase price of US$4.25 per share (the "Purchase Price"), for an aggregate purchase price of US$27.5 million. The purchased shares represent approximately 9.7% of the outstanding common shares of the Company as of October 13, 2009. Following the cancellation of the common shares purchased under the Offer, 60,163,885 common shares of the Company will remain issued and outstanding.

Based on the final report of the Depository, 7,209,211 common shares were properly tendered to the Offer at or below the Purchase Price. Subject to certain limited exceptions described in the offer to purchase and issuer bid circular for the Offer filed with securities regulatory authorities in Canada and the United States on September 1, 2009, shareholders who tendered their common shares to the Offer at a price equal to or less than the Purchase Price will have approximately 90% of their deposited common shares purchased by the Company. Payment for all common shares accepted for purchase under the Offer will be carried out promptly by the Depository. Because the paid up capital per common share exceeds the Purchase Price, shareholders will not be deemed to receive a dividend upon payment for their common shares.

Common shares tendered to the Offer but not purchased, i
'/>"/>

SOURCE Cardiome Pharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardiome Pharma Corp. Announces Commencement of US$27.5 Million Tender Offer
2. Cardiome Announces Upcoming Presentation Of Results Of Phase 2b Clinical Trial Of Vernakalant (Oral) At The European Society Of Cardiology Congress 2009
3. Cardiome Pharma Corp. Announces Tender Offer To Purchase Up To US$27.5 Million Of Its Common Shares
4. Atherotech Adds New Cardiometabolic Tests Amid Strong 2009 Growth
5. Cardiome to Hold Conference Call
6. Cardiome Announces Management Transition
7. Cardiome Achieves Milestone From Collaboration With Merck Co., Inc.
8. Cardiome Announces That Collaboration and License Agreement with Merck & Co., Inc. Now Effective
9. Cardiome Reports First Quarter Results
10. Cardiome to Hold Conference Call
11. CardioCareLive.com, First Ever Online Cardiometabolic Conference, Revolutionizes Continuing Medical Education for Cardiovascular Healthcare Professionals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... ... August 03, 2015 , ... According to an opinion piece published July 28 ... leads to one pound of weight loss may not be accurate. While this system may ... one pound of fat varies – based both on the individual and at what point ...
(Date:8/3/2015)... , ... August 03, 2015 , ... ... in 2015 MarketingProfs Bright Bulb B2B Awards. , The MarketingProfs Bright Bulb B2B ... B2B brands. BESLER Consulting's campaign for the launch of their Readmissions Analytics product ...
(Date:8/3/2015)... ... August 03, 2015 , ... ... that while an overwhelming number of Hispanics believe people can positively affect their ... percent of participants queried said making diet changes was important. Far fewer participants ...
(Date:8/3/2015)... ... August 03, 2015 , ... Social impact organization’s #HelpOneHelpMany approach ... – Since winning a South by Southwest® (SXSW®) Interactive Innovation Award in the ... mission is to develop technology for the sake of humanity – continues to ...
(Date:8/3/2015)... ... ... AxoGen, Inc. (NASDAQ: AXGN), a leader in developing and marketing innovative surgical solutions ... Wednesday, August 12, 2015 at 9:45am (ET) at Le Parker Meridien in New York, ... be accessed via the investor relations section of the Company’s website. , About AxoGen, ...
Breaking Medicine News(10 mins):Health News:Article Dispelling Weight Loss Myth Correctly Emphasizes the Complicated and Difficult Nature of Weight Loss, Says Dr. Michael Feiz 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 2Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 3Health News:Hispanics More Likely to Struggle with Misinformation About Diabetes 4Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 2Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 3Health News:Not Impossible Earns Top Awards for Technologies Benefiting Humanity 4Health News:AxoGen, Inc. to Present at the Wedbush Healthcare Conference 2
... insulin has been found to suppress the expression in ... pathogenesis of Alzheimer,s disease, according to new clinical research ... March online in the Journal of Clinical Endocrinology ... powerful, new role to play in fighting Alzheimer,s disease. ...
... the Centers for Disease Control and Prevention (CDC) ... (HICPAC) outline steps to eliminate bloodstream infections in ... most deadly and costly healthcare-associated infections (HAIs). ... Intravascular Catheter-Related Infections" will be published in its ...
... parents get their information about vaccines from their children,s ... parents, friends and family members and even celebrities as ... of a national survey conducted by University of Michigan ... of information in regards to vaccines, as well as ...
... 1 (HealthDay News) -- Exercise is a good way for ... says an expert. "People who have arthritis are often ... but the condition will only get worse if people don,t ... Center for Fitness in Maywood, Ill., said in a news ...
... brand new technology that promises a range of applications ... reached another world first in its development. This milestone ... and Technology Facilities Council,s (STFC) Daresbury Laboratory in Cheshire. ... start up of the pioneering EMMA accelerator which is ...
... to quickly distinguish individuals with active tuberculosis (TB) from ... the preliminary results of the study will be confirmed ... could allow more effective strategies to control the spread ... performed by a group of scientists from the Catholic ...
Cached Medicine News:Health News:Insulin could be Alzheimer's therapy 2Health News:CDC issues updated bloodstream infection prevention guidelines 2Health News:CDC issues updated bloodstream infection prevention guidelines 3Health News:U-M experts: Parents trust doctors most when it comes to information about vaccine safety 2Health News:Exercise Is Key for People With Arthritis: Expert 2Health News:EMMA milestone beams its way to a world first 2Health News:EMMA milestone beams its way to a world first 3Health News:A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease 2Health News:A new experimental diagnostic test able to quickly distinguish infection from tuberculosis disease 3
(Date:8/3/2015)... 2015 OmniSeq, LLC today announced the ... OmniSeq SM Genomic Network.  Recently, OmniSeq officially ... and announced it was making available a suite ... approach to genomic diagnostics that provides actionable results ... a rapidly expanding, multidisciplinary cancer care center that ...
(Date:8/3/2015)... 3, 2015 According to ... Research "Global Market Study on Physiotherapy Equipment - ... Growth by 2022", the global physiotherapy equipment market is estimated ... of 2015 and is expected to grow at ... to account for US$23.7 Bn by 2022. ...
(Date:8/3/2015)... -- CytRx Corporation (NASDAQ: CYTR ), a biopharmaceutical research ... results for the three months ended June 30, 2015, ... upcoming milestones for its clinical development programs. ... for CytRx. Enrollment in our ongoing pivotal global Phase ... (STS) continues on track to be completed in the ...
Breaking Medicine Technology:OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 2OmniSeq Adds Wilmot Cancer Institute to its Collaboration-Based Treatment Network 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4CytRx Reports 2015 Second Quarter Financial Results 2CytRx Reports 2015 Second Quarter Financial Results 3CytRx Reports 2015 Second Quarter Financial Results 4CytRx Reports 2015 Second Quarter Financial Results 5CytRx Reports 2015 Second Quarter Financial Results 6CytRx Reports 2015 Second Quarter Financial Results 7CytRx Reports 2015 Second Quarter Financial Results 8CytRx Reports 2015 Second Quarter Financial Results 9CytRx Reports 2015 Second Quarter Financial Results 10CytRx Reports 2015 Second Quarter Financial Results 11CytRx Reports 2015 Second Quarter Financial Results 12CytRx Reports 2015 Second Quarter Financial Results 13CytRx Reports 2015 Second Quarter Financial Results 14
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: